Eli Lilly and Company (LLY)
LLY trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$1166.51
-1.36% on the day
Market cap
$1.10T
Mega cap
Revenue · 2025
$65.2B
+44.7% on 2024
Net income · 2025
$20.6B
31.7% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | LLY on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000059478 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | IN |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $65.2B |
| Net income | $20.6B |
| Operating income | Not in SEC XBRL data |
| Net margin | 31.7% |
| Operating margin | Operating income not reported |
| Revenue growth | +44.7% |
| Cash | $7.3B |
| Total assets | $112.5B |
| P/E (computed) | 53.2× |
| P/S (computed) | 16.8× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B2 | 2026-05-08 |
| Latest annual report | 10-K | 2026-02-12 |
| Latest quarterly / interim | 10-Q | 2026-08-05 |
| Latest current report | 8-K | 2026-08-05 |
| Latest proxy | DEFA14A | 2026-03-20 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +2.0% |
| 1 month | +6.7% |
| 3 months | +3.7% |
| Year to date | +12.8% |
| 1 year | +48.0% |
| From 52-week high | -5.3% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| JNJ | Johnson & Johnson | $248.61 | -5.73% | $599.1B |
| ABBV | AbbVie Inc. | $274.36 | -2.40% | $484.8B |
| MRK | Merck & Company Inc. Common Stock (new) | $141.98 | -2.39% | $350.3B |
| NVS | Novartis AG | $142.41 | -0.99% | $271.7B |
| AZN | AstraZeneca PLC | $155.82 | -1.58% | $241.6B |
| ABT | Abbott Laboratories | $102.61 | +0.78% | $177.6B |
| NVO | Novo Nordisk A/S | $38.06 | -1.35% | $168.5B |
| PFE | Pfizer Inc. | $28.37 | -0.11% | $161.7B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier